Patient Power Secures Landmark Funding for Rare Disease Research

WASHINGTON, D.C. – February 03, 2026 – In a rare display of unity, Congress has passed, and the President has signed into law, a sweeping federal funding package that provides a critical lifeline for hundreds of thousands of Americans living with rare neuromuscular diseases. The Consolidated Appropriations Act, 2026, hailed by patient advocates as a monumental achievement, directs billions toward biomedical research, accelerates access to therapies, and dismantles barriers to care, marking a new chapter of hope for a community long defined by its resilience.

The Muscular Dystrophy Association (MDA), which has championed the cause for 75 years, applauded the legislation as the culmination of a persistent, multi-year campaign waged not in the halls of power, but from the living rooms, clinics, and online forums of families across the nation.

A Victory Forged by Advocacy

This legislative victory was not born overnight. It is the direct result of a relentless grassroots movement. According to the MDA, advocates held over 250 meetings with lawmakers, sent more than 7,000 letters, and made countless phone calls over the last five years to ensure the needs of the neuromuscular disease community were heard.

“This moment belongs to the hundreds of advocates in our community who never stopped showing up,” said Paul Melmeyer, MPP, Executive Vice President of Public Policy and Advocacy at MDA. “Their partnership with the Muscular Dystrophy Association, sharing their stories, educating lawmakers, and pushing for bipartisan solutions, helps ensure that people living with neuromuscular diseases can live longer, healthier, and more independent lives.”

That personal impact is the driving force behind the movement. For advocates like Lily Sander, an MDA National Ambassador who lives with Charcot-Marie-Tooth disease—a condition with no approved treatment—the fight is deeply personal. She has spent years urging policymakers to act with urgency.

“This funding represents hope, not just for today, but for the future,” said Lily. “Families like mine have never stopped advocating because we know progress is possible. Seeing Congress come together in a bipartisan way shows that our voices matter and that change can happen when we refuse to give up.”

Fueling the Engine of Discovery

At the heart of the legislation is a $48.7 billion allocation for the National Institutes of Health (NIH), representing a 1% increase. While modest, this funding is crucial for sustaining the forward momentum of biomedical research. In the context of rising inflation, even a small increase is considered a significant win, preventing the devastating delays and cancellations of research projects that cuts would have triggered.

More importantly, the bill includes policy language that protects the stability of long-term research by limiting the forward funding of grants and prohibiting arbitrary caps on indirect costs. These costs are essential for maintaining the infrastructure of the universities and labs where groundbreaking discoveries are made. Experts note that every dollar invested in NIH research generates approximately $2.60 in economic output, making it a powerful driver of both health and prosperity.

“For more than 75 years, the Muscular Dystrophy Association has helped build the foundation of this field—advancing research, expanding multidisciplinary care, and elevating patient voices,” said Sharon Hesterlee, PhD, President and CEO at MDA. “Federal funding is critical to maintaining that momentum.” She noted that such efforts have contributed to more than 30 FDA-approved treatments in just the past decade.

Accelerating Hope for ALS and Pediatric Care

The bill also takes direct aim at specific, urgent needs within the community. It allocates $90 million to the ACT for ALS program, ensuring the continued implementation of a law designed to speed up access to investigational therapies for people with Amyotrophic Lateral Sclerosis (ALS). This funding supports a public-private partnership, including the Accelerating Medicines Partnership® for ALS (AMP® ALS), which seeks to identify and validate promising biomarkers to dramatically accelerate the development of effective treatments.

For the youngest patients, the passage of the Accelerating Kids’ Access to Care Act within the package is a game-changer. For years, children with rare and complex conditions who rely on Medicaid have faced bureaucratic hurdles and life-threatening delays when trying to see specialists across state lines. This new law streamlines the screening and enrollment process for providers, allowing children to access the unique expertise they need, regardless of geography.

Reigniting a Critical Incentive for Pediatric Therapies

Perhaps one of the most impactful provisions is the reauthorization of the Rare Pediatric Disease Priority Review Voucher (RPD PRV) Program through the Give Kids a Chance Act. The program, which incentivizes companies to develop treatments for rare pediatric diseases, had lapsed in 2024, casting a chill over investment in the sector.

The RPD PRV program awards a company that gains FDA approval for a qualifying pediatric rare disease drug a voucher that can be used to expedite the FDA review of any other drug in its pipeline by about four months. These vouchers are transferable and have been sold for over $100 million, providing a crucial financial injection for the small and emerging biotech firms that perform much of this high-risk research. Since 2012, the program has been instrumental in the development of therapies for Duchenne muscular dystrophy, spinal muscular atrophy, and other conditions that previously had no approved treatments.

The recent lapse in the program had caused significant uncertainty, with one survey of biotech executives revealing that 35% had delayed or canceled pediatric rare disease programs. Its reauthorization through September 2029 is expected to prevent an estimated $4 billion in lost reinvestment, securing a vital pathway for innovation. This legislative package, therefore, does more than just provide funding; it restores confidence and stability to the entire rare disease ecosystem, ensuring that the partnership between patient advocacy, scientific research, and industry innovation can continue to turn hope into tangible therapies.